BioChemics Overview
- Year Founded
-
1989
- Status
-
Out of Business
- Employees
-
11
- Latest Deal Type
-
Out of Business
BioChemics General Information
Description
Developer of transdermal drug delivery technology designed to offer treatment for the skin. The company's technology offer products that deliver a wide variety of active drug molecules deep into the skin tissue or the bloodstream and can target specific areas directly with small doses of a drug avoiding the need to deliver massive oral doses, which create additional side effects, enabling patients to get advanced care for their dermal problems.
Contact Information
Website
biochemics.comCorporate Office
- 99 Rosewood Drive
- Suite 270
- Danvers, MA 01923
- United States
Corporate Office
- 99 Rosewood Drive
- Suite 270
- Danvers, MA 01923
- United States
BioChemics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Out of Business | 08-Feb-2020 | Completed | Out of Business | |||
| 5. Later Stage VC (Series E) | 01-Jan-2012 | Completed | Clinical Trials - Phase 2 | |||
| 4. Later Stage VC (Series D) | 03-Oct-2008 | Completed | Startup | |||
| 3. Later Stage VC (Series C) | 30-Dec-2002 | Completed | Startup | |||
| 2. Early Stage VC (Series B) | Completed | Startup | ||||
| 1. Early Stage VC (Series A) | Completed | Startup |
BioChemics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Non-Voting Series E | ||||||||
| Series D | ||||||||
| Series C | ||||||||
| Series B | 1,500,000 | $0.010000 | $6.62 | $6.62 | 1x | $6.62 | 4.89% | |
| Series A | 3,000,000 | $0.010000 | $6.62 | $6.62 | 1x | $6.62 | 0.29% |
BioChemics Patents
BioChemics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-3624770-A1 | Transdermally-delivered combination drug therapy for pain | Inactive | 15-May-2017 | ||
| US-10624867-B2 | Transdermally-delivered combination drug therapy for pain | Active | 15-May-2017 | ||
| US-20180325851-A1 | Transdermally-delivered combination drug therapy for pain | Active | 15-May-2017 | ||
| WO-2018213071-A1 | Transdermally-delivered combination drug therapy for pain | Inactive | 15-May-2017 | ||
| CA-2906765-A1 | Topical formulations and methods for drug delivery | Inactive | 15-Mar-2013 | A61K31/198 |
BioChemics Signals
BioChemics FAQs
-
When was BioChemics founded?
BioChemics was founded in 1989.
-
Where is BioChemics headquartered?
BioChemics is headquartered in Danvers, MA.
-
What is the size of BioChemics?
BioChemics has 11 total employees.
-
What industry is BioChemics in?
BioChemics’s primary industry is Drug Delivery.
-
Is BioChemics a private or public company?
BioChemics is a Private company.
-
What is BioChemics’s current revenue?
The current revenue for BioChemics is .
-
How much funding has BioChemics raised over time?
BioChemics has raised $20M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process